FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247366159> ?p ?o ?g. }

• W4247366159 endingPage "5108" @default.
• W4247366159 startingPage "5108" @default.
• W4247366159 abstract "5108 Background: To evaluate the efficacy and toxicity of the sequential administration of paclitaxel-carboplatin (T/C) and paclitaxel-liposomal doxorubicin (T/D) as 1st line treatment in pts with ovarian cancer. Methods: From 2/2001 to 6/2002, 52 pts with histologically proven, FIGO stage III/IV ovarian cancer were enrolled. No prior chemotherapy, radiotherapy or endocrine therapy was allowed. Other eligibility criteria included age<75 years, PS 0–2, life expectance > 6 months, adequate hepatic, renal, cardiac and bone marrow function. Median age was 60 years (range 40 to 74). In 36 pts cytoreductive surgery was performed. Patients received 4 cy of Paclitaxel 175mg/m2, 3-h infusion and Carboplatin 6 AUC both on day 1 every 3 weeks, followed by 4 additional cy of liposomal doxorubicin 40mg/m2 and Carboplatin 6 AUC both on day 1 every 3 weeks. Results: At the time of the present analysis, 41 patients were evaluable for toxicity and 39 for response. A total of 284 cy were delivered (median cy: 8/pt). Grade 3–4 neutropenia occurred in 24.7% of cy, thrombocytopenia in 6.4%. There were no episodes of febrile neutropenia. G-CSF was required in 49.6% of the cy and non-hematological toxicity was mild except alopecia. Chemotherapy was delayed in 20.4% of the cycles (median delay: 7 days, range 4–44) but due to hematological toxicity in only 9.1% of the cy. The median follow-up was 11.5 months (range 1–29 mo). 20 (51.2%) and 12 (30.8%) pts achieved CR and PR with the T/C regimen, respectively and 7 (18%) had SD. The administration of T/D regimen resulted in 3 (15.8%) additional CRs. The overall response rate was 66% (CR 44%, PR 22%), with a median duration of response of 10.2 months (range 1–25.8 mo); the time to progression was 12.1 months (range 1–28.9 mo) and the median survival has not yet been reached. Conclusions: The results of the analysis indicate that the sequential administration of paclitaxel-carboplatin followed by paclitaxel-liposomal doxorubicin is an active regimen with acceptable toxicity as a 1st line treatment in patients with ovarian cancer. No significant financial relationships to disclose." @default.
• W4247366159 created "2022-05-12" @default.
• W4247366159 creator A5014087122 @default.
• W4247366159 creator A5016051621 @default.
• W4247366159 creator A5018500204 @default.
• W4247366159 creator A5024001699 @default.
• W4247366159 creator A5028987624 @default.
• W4247366159 creator A5043849331 @default.
• W4247366159 creator A5054544610 @default.
• W4247366159 creator A5062712127 @default.
• W4247366159 creator A5074699018 @default.
• W4247366159 creator A5088449150 @default.
• W4247366159 date "2004-07-15" @default.
• W4247366159 modified "2023-09-26" @default.
• W4247366159 title "Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as 1st line treatment in patients with ovarian cancer: A multicenter phase II clinical trial" @default.
• W4247366159 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.5108" @default.
• W4247366159 hasPublicationYear "2004" @default.
• W4247366159 type Work @default.
• W4247366159 citedByCount "0" @default.
• W4247366159 crossrefType "journal-article" @default.
• W4247366159 hasAuthorship W4247366159A5014087122 @default.
• W4247366159 hasAuthorship W4247366159A5016051621 @default.
• W4247366159 hasAuthorship W4247366159A5018500204 @default.
• W4247366159 hasAuthorship W4247366159A5024001699 @default.
• W4247366159 hasAuthorship W4247366159A5028987624 @default.
• W4247366159 hasAuthorship W4247366159A5043849331 @default.
• W4247366159 hasAuthorship W4247366159A5054544610 @default.
• W4247366159 hasAuthorship W4247366159A5062712127 @default.
• W4247366159 hasAuthorship W4247366159A5074699018 @default.
• W4247366159 hasAuthorship W4247366159A5088449150 @default.
• W4247366159 hasConcept C121608353 @default.
• W4247366159 hasConcept C126322002 @default.
• W4247366159 hasConcept C126894567 @default.
• W4247366159 hasConcept C141071460 @default.
• W4247366159 hasConcept C143998085 @default.
• W4247366159 hasConcept C2776694085 @default.
• W4247366159 hasConcept C2777063308 @default.
• W4247366159 hasConcept C2777292972 @default.
• W4247366159 hasConcept C2778239845 @default.
• W4247366159 hasConcept C2778850193 @default.
• W4247366159 hasConcept C2780427987 @default.
• W4247366159 hasConcept C2781451048 @default.
• W4247366159 hasConcept C29730261 @default.
• W4247366159 hasConcept C71924100 @default.
• W4247366159 hasConcept C90924648 @default.
• W4247366159 hasConceptScore W4247366159C121608353 @default.
• W4247366159 hasConceptScore W4247366159C126322002 @default.
• W4247366159 hasConceptScore W4247366159C126894567 @default.
• W4247366159 hasConceptScore W4247366159C141071460 @default.
• W4247366159 hasConceptScore W4247366159C143998085 @default.
• W4247366159 hasConceptScore W4247366159C2776694085 @default.
• W4247366159 hasConceptScore W4247366159C2777063308 @default.
• W4247366159 hasConceptScore W4247366159C2777292972 @default.
• W4247366159 hasConceptScore W4247366159C2778239845 @default.
• W4247366159 hasConceptScore W4247366159C2778850193 @default.
• W4247366159 hasConceptScore W4247366159C2780427987 @default.
• W4247366159 hasConceptScore W4247366159C2781451048 @default.
• W4247366159 hasConceptScore W4247366159C29730261 @default.
• W4247366159 hasConceptScore W4247366159C71924100 @default.
• W4247366159 hasConceptScore W4247366159C90924648 @default.
• W4247366159 hasIssue "14_suppl" @default.
• W4247366159 hasLocation W42473661591 @default.
• W4247366159 hasOpenAccess W4247366159 @default.
• W4247366159 hasPrimaryLocation W42473661591 @default.
• W4247366159 hasRelatedWork W2041841240 @default.
• W4247366159 hasRelatedWork W2053778437 @default.
• W4247366159 hasRelatedWork W2072767112 @default.
• W4247366159 hasRelatedWork W2105623825 @default.
• W4247366159 hasRelatedWork W2157919202 @default.
• W4247366159 hasRelatedWork W2311734504 @default.
• W4247366159 hasRelatedWork W2320097775 @default.
• W4247366159 hasRelatedWork W2410995755 @default.
• W4247366159 hasRelatedWork W2417634857 @default.
• W4247366159 hasRelatedWork W2968124559 @default.
• W4247366159 hasVolume "22" @default.
• W4247366159 isParatext "false" @default.
• W4247366159 isRetracted "false" @default.
• W4247366159 workType "article" @default.